Identification of a metabolic biomarker panel in rats for prediction of acute and idiosyncratic hepatotoxicity

Computational and Structural Biotechnology Journal

Volumn 10, Issue 17, 2014, Pages 78-89

  Sun, Jinchun ^a   Slavov, Svetoslav ^a   Schnackenberg, Laura K ^a   Ando, Yosuke ^a,b   Greenhaw, James ^a   Yang, Xi ^a   Salminen, William ^a,c   Mendrick, Donna L ^a   Beger, Richard ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b DAIICHI SANKYO CO   (Japan)

^c PAREXEL INTERNATIONAL   (United States)

Author keywords

Acute hepatotoxicity; Biomarker panel; Idiosyncratic hepatotoxicity; Metabolomics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CARBON TETRACHLORIDE; DANTROLENE; DRUG METABOLITE; FELBAMATE; MELOXICAM; METFORMIN; PARACETAMOL; PENICILLIN V POTASSIUM;

ACCURACY; ACUTE LIVER FAILURE; ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL CHEMISTRY; CONTROLLED STUDY; HISTOPATHOLOGY; LIVER NECROSIS; LIVER TOXICITY; MALE; METABOLOMICS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; RAT; TRANSCRIPTOMICS;

RATTUS;

EID: 84933524688     PISSN: None     EISSN: 20010370     Source Type: Journal    
DOI: 10.1016/j.csbj.2014.08.001     Document Type: Article

References (60)

1. Fannin RD, Russo M, O'Connell TM, Gerrish K, Winnike J.H., Macdonald J., et al. Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology 2010; 51: 227-36.
2. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 2007; 6:673-84.
3. Amacher DE. The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury. Expert Opin Drug Metab Toxicol 2012; 8:335-47.
4. Sherman KE. Alanine aminotransferase in clinical practice. A review. Arch Intern Med 1991; 151:260-5.
5. Zeisel SH, Da Costa KA, Franklin PD, Alexander EA, Lamont JT, Sheard N.F., et al. Choline, an essential nutrient for humans. FASEB J 1991; 5:2093-8.
6. Amacher DE. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol 1998; 27:119-30.
7. Dufour DR, Lott JA, Nolte F.S., Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000; 46:2050-68.
8. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001; 24:483-90.
9. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4:489-99.
10. Xu JJ, Henstock PV, Dunn M.C., Smith AR, Chabot JR, de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 2008; 105:97-105.
11. Ozer J, Ratner M, Shaw M., Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008; 245:194-205.
12. Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther 2012; 92:332-9.
13. Bowlus CL, Gershwin ME. The diagnosis of primary biliary cirrhosis. Autoimmun Rev 2014; 13:441-4.
14. Gregus Z. Mechanisms of toxicity. New York: McGraw Hill; 2008.
15. Jackson AF, Williams A, Recio L., Waters MD, Lambert IB, Yauk CL. Case study on the utility of hepatic global gene expression profiling in the risk assessment of the carcinogen furan. Toxicol Appl Pharmacol 2013; 274:63-77.
16. ∗5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41:816-9.
17. Andrade RJ, Lucena MI, Alonso A, Garcia-Cortes M, Garcia-Ruiz E, Benitez R, et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004; 39:1603-12.
18. Yang X, Greenhaw J, Shi Q., Su Z, Qian F, Davis K., et al. Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity. Toxicol Sci 2012; 125: 335-44.
19. Bell LN, Vuppalanchi R, Watkins P.B., Bonkovsky HL, Serrano J, Fontana RJ, et al. Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther 2012; 35:600-12.
20. Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R., Bemis KG, Wang M, et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010; 51:111-20.
21. Mattes W, Davis K, Fabian E., Greenhaw J, Herold M, Looser R., et al. Detection of hep-atotoxicity potential with metabolite (metabolomics) profiling of rat plasma. Toxicol Lett 2014 S0378-4274.
22. Sun J, Ando Y, Ahlbory-Dieker D, Schnackenberg L.K., Yang X., Greenhaw J, et al. Systems biology investigation to discover metabolic biomarkers of acetaminophen-induced hepatic injury using integrated transcriptomics and metabolomics. J Mol Biomark Diagn 2013:S1.
23. Sun J, Schmitt T, Schnackenberg L.K., Pence L., Ando Y, Greenhaw J, et al. Comprehensive analysis of alterations in lipid and bile acid metabolism by carbon tetrachloride using integrated transcriptomics and metabolomics. Metabolomics 2014. http://dx.doi.org/10.1007/s11306-014-0665-7 [Epub. ahead of print].
24. Sun J, Schnackenberg LK, Khare S, Yang X., Greenhaw J, Salminen W, et al. Evaluating effects of penicillin treatment on the metabolome of rats. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 932:134-43.
25. Knodell RG, Ishak KG, Black W.C., Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-5.
26. Sun J, Schnackenberg LK, Hansen D.K., Beger RD. Study of valproic acid-induced endogenous and exogenous metabolite alterations using LC-MS-based metabolomics. Bioanalysis 2010; 2:207-16.
27. Sun J, Von Tungeln LS, Hines W, Beger RD. Identification of metabolite profiles of the catechol-O-methyl transferase inhibitor tolcapone in rat urine using LC/MS-based metabonomics analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 2557-65.
28. McJunkin B, Barwick KW, Little W.C., Winfield JB. Fatal massive hepatic necrosis following acetaminophen overdose. JAMA 1976; 236:1874-5.
29. Andrade RJ, Lucena MI, Garcia-Escano MD, Camargo R. Severe idiosyncratic acute hepatic injury caused by paracetamol. J Hepatol 1998; 28:1078.
30. Kamel R, El Morsy EM. Hepatoprotective effect of methylsulfonylmethane against carbon tetrachloride-induced acute liver injury in rats. Arch Pharm Res 2013; 36: 1140-8.
31. Dieckhaus CM, Thompson CD, Roller S.G., Macdonald TL. Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem Biol Interact 2002; 142:99-117.
32. Utili R, Boitnott JK, Zimmerman HJ. Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 1977; 72:610-6.
33. Shapiro B, Ruff R. Disorders of skeletal muscle membrane excitability: myotonia congenita, paramyotonia congenita, periodic paralysis, and related disorders. Butterworth-Heinemann; 2002.
34. Santucci L, Fiorucci S, Patoia L., Di Matteo FM, Brunori PM, Morelli A. Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens. Dig Dis Sci 1995; 40:2074-80.
35. Dickson SD, Salazar KC. Diagnosis and management of immediate hypersensitivity reactions to cephalosporins. Clin Rev Allergy Immunol 2013; 45:131-42.
36. Miralles-Linares F, Puerta-Fernandez S, Bernal-Lopez MR, Tinahones FJ, Andrade R.J., Gomez-Huelgas R. Metformin-induced hepatotoxicity. Diabetes Care 2012; 35:e21.
37. Frebourg T, Bercoff E, Manchon N., Senant J, Basuyau JP, Breton P, et al. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 1988; 62:2287-90.
38. Dufour DR, Lott JA, Nolte F.S., Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000; 46:2050-68.
39. Watkins PB, Zimmerman HJ, Knapp M.J., Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271:992-8.
40. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4:489-99.
41. Olson S, Robinson S, Giffin R. Accelerating the development of biomarkers for drug safety. Workshop Summary; 2009 42-57.
42. Mattes WB, Kamp HG, Fabian E, Herold M., Krennrich G, Looser R, et al. Prediction of clinically relevant safety signals of nephrotoxicity through plasma metabolite profiling. Biomed Res Int 2013; 2013:202497.
43. Legido-Quigley C, McDermott L, Vilca-Melendez H, Murphy G.M., Heaton N., Lindon JC, et al. Bile UPLC-MS fingerprinting and bile acid fluxes during human liver transplantation. Electrophoresis 2011; 32:2063-70.
44. Chen C, Krausz KW, Shah Y.M., Idle JR, Gonzalez FJ. Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol 2009; 22:699-707.
45. Bhattacharyya S, Yan K, Pence L., Simpson PM, Gill P, Letzig LG, et al. Targeted liquid chromatography-mass spectrometry analysis of serum acylcarnitines in acetaminophen toxicity in children. Biomark Med 2014; 8:147-59.
46. Kalgutkar AS, Vaz AD, Lame M.E., Henne KR, Soglia J, Zhao SX, et al. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab Dispos 2005; 33:243-53.
47. Saravanan N, Rajasankar S, Nalini N. Antioxidant effect of 2-hydroxy-4-methoxy benzoic acid on ethanol-induced hepatotoxicity in rats. J Pharm Pharmacol 2007; 59:445-53.
48. James LP, Letzig L, Simpson P.M., Capparelli E., Roberts DW, Hinson JA, et al. Pharmacokinetics of acetaminophen-protein adducts inadults with acetaminophen overdose and acute liver failure. Drug Metab Dispos 2009; 37:1779-84.
49. Burcham PC, Harman AW. Acetaminophen toxicity results in site-specific mitochon-drial damage in isolated mouse hepatocytes. J Biol Chem 1991; 266:5049-54.
50. Pan X, Hussain FN, Iqbal J, Feuerman M.H., Hussain MM. Inhibiting proteasomal degradation of microsomal triglyceride transfer protein prevents CCl4-induced steatosis. J Biol Chem 2007; 282:17078-89.
51. Kapetanovic IM, Torchin CD, Strong J.M., Yonekawa WD, Lu C, Li AP, et al. Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chem Biol Interact 2002; 142:119-34.
52. Arnold Jr TH, Epps 3rd JM, Cook HR, Hamrick ME. Dantrolene sodium: urinary metabolites and hepatotoxicity. Res Commun Chem Pathol Pharmacol 1983; 39: 381-98.
53. Stepan AF, Walker DP, Bauman J, Price D.A., Baillie TA, Kalgutkar AS, et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 2011; 24:1345-410.
54. ∗5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41:816-9.
55. Lemasters JJ, Nieminen AL, Qian T, Trost L.C., Elmore SP, Nishimura Y, et al. The mito-chondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998; 1366:177-96.
56. McGill MR, Williams CD, Xie Y, Ramachandran A., Jaeschke H. Acetaminophen-induced liver injury in rats and mice: comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity. Toxicol Appl Pharmacol 2012; 264:387-94.
57. Lee KS, Oh SJ, Kim H.M., Lee KH, Kim SK. Assessment of reactive metabolites in drug-induced liver injury. Arch Pharm Res 2011; 34:1879-86.
58. Yang X, Greenhaw J, Ali A., Shi Q, Roberts DW, Hinson J.A., et al. Changes in mouse liver protein glutathionylation after acetaminophen exposure. J Pharmacol Exp Ther 2012; 340:360-8.
59. Sancar A, Sancar GB. DNA repair enzymes. Annu Rev Biochem 1988; 57:29-67.
60. Selman C, Kerrison ND, Cooray A, Piper M.D., Lingard SJ, Barton RH, et al. Coordinated multitissue transcriptional and plasma metabonomic profiles following acute caloric restriction in mice. Physiol Genomics 2006; 27:187-200.